Iovance Biotherapeutics announces common stock offering

|About: Iovance Biotherapeutics, Inc. (IOVA)|By:, SA News Editor

Iovance Biotherapeutics (NASDAQ:IOVA) initiates a public offering of common stock.

Underwriters over-allotment is an additional 15% of the common stock.

Iovance intends to use the proceeds to fund the expansion of its organization to support the commercial launch of lifileucel, to fund clinical trials and for other general corporate purposes.

Price, volume and terms have yet to be announced.

Subscribe for full text news in your inbox